Wolverine Trading
VRTX icon

Wolverine Trading’s Vertex Pharmaceuticals VRTX Stock Holding History

Wolverine Trading’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$8.08M Buy
20,449
+2,854
+16% +$1.19M 0.01% 1054
2025
Q2 		$7.76M Buy
17,595
+16,180
+1,143% +$7.46M 0.01% 808
2025
Q1 		$697K Sell
1,415
-16,753
-92% -$7.81M ﹤0.01% 2594
2024
Q4 		$7.26M Buy
18,168
+9,502
+110% +$4.4M 0.01% 969
2024
Q3 		$4.01M Buy
8,666
+5,719
+194% +$2.75M ﹤0.01% 1193
2024
Q2 		$1.38M Sell
2,947
-11,124
-79% -$4.83M ﹤0.01% 1892
2024
Q1 		$5.88M Sell
14,071
-15,113
-52% -$6.39M 0.01% 913
2023
Q4 		$11.9M Buy
29,184
+4,458
+18% +$1.65M 0.01% 652
2023
Q3 		$8.6M Buy
24,726
+16,977
+219% +$5.94M 0.01% 695
2023
Q2 		$2.7M Buy
7,749
+185
+2% +$62.3K ﹤0.01% 1301
2023
Q1 		$2.36M Buy
+7,564
New +$2.27M ﹤0.01% 1270
2022
Q4 		– Sell
-1,598
Closed -$487K – 5121
2022
Q3 		$468K Buy
+1,598
New +$460K ﹤0.01% 2663
2022
Q2 		– Sell
-3,423
Closed -$916K – 5828
2022
Q1 		$878K Sell
3,423
-15,146
-82% -$3.59M ﹤0.01% 2578
2021
Q4 		$4.13M Sell
18,569
-4,402
-19% -$856K ﹤0.01% 1274
2021
Q3 		$4.19M Buy
22,971
+588
+3% +$115K ﹤0.01% 1445
2021
Q2 		$4.41M Buy
22,383
+6,840
+44% +$1.43M 0.01% 1256
2021
Q1 		$3.31M Sell
15,543
-3,635
-19% -$798K 0.01% 1451
2020
Q4 		$4.46M Buy
19,178
+7,804
+69% +$1.79M 0.01% 1140
2020
Q3 		$3.08M Sell
11,374
-4,631
-29% -$1.28M 0.01% 1158
2020
Q2 		$4.56M Buy
+16,005
New +$4.34M 0.01% 863
2020
Q1 		– Sell
-18,621
Closed -$4.27M – 5380
2019
Q4 		$4.08M Buy
18,621
+8,441
+83% +$1.71M 0.01% 1258
2019
Q3 		$1.7M Buy
+10,180
New +$1.8M ﹤0.01% 1550
2018
Q1 		– Sell
-13,293
Closed -$2.17M – 5910
2017
Q4 		$1.99M Buy
13,293
+10,567
+388% +$1.56M 0.01% 1559
2017
Q3 		$414K Buy
+2,726
New +$410K ﹤0.01% 2842

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wolverine Trading's VRTX Position: Q3 2025 in Review

Wolverine Trading increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2025, buying an estimated $1.19M and bringing the position to 20,449 shares worth $8.08M. The position accounts for 0.01% of the portfolio, ranked #1054.

Wolverine Trading first reported a position in VRTX in Q3 2017 and has held it in 24 quarters since. The position peaked at $11.9M in Q4 2023. 1,521 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Wolverine Trading held 20,449 shares of Vertex Pharmaceuticals worth $8.08M as of Q3 2025.
  • Wolverine Trading bought 2,854 Vertex Pharmaceuticals shares in Q3 2025, an estimated $1.19M.
  • Vertex Pharmaceuticals made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #1054 holding.
  • Wolverine Trading first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
  • Wolverine Trading's Vertex Pharmaceuticals position peaked at $11.9M in Q4 2023.
  • 1,521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.